AGIO - Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today? | Benzinga
Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response.
Statistical significance was also achieved for both key secondary endpoints associated with a change from baseline in FACIT-Fatigue Score and hemoglobin concentration.
A total of 194 patients were enrolled in the study, with 130 randomized to mitapivat 100 mg twice-daily (BID) and 64 randomized to matched placebo.
122 (93.8%) ...